https://orcid.org/0000-0002-7480-4437
References
- Schunack W. What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther. 1987;1(Suppl 1):493–503.
- de Mattos ÂZ, Marchese GM, Fonseca BB, et al. Antisecretory treatment for pediatric gastroesophageal reflux disease – a systematic review. Arq Gastroenterol. 2017;54(4):271–280.
- Slaughter JL, Stenger MR, Reagan PB, et al. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States children’s hospitals. J Pediatr. 2016;174:63–70.e3.
- FDA Requests Removal of All Ranitidine Products (Zantac) from the Market | FDA. [cited 2020 Dec 22]. Accessed from: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.
- Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity Amounts Above the Levels Established by FDA | FDA. [citeed 2021 April 13]. Accessed from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due.
- Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–342.
- Pali-Schöll I, Jensen-Jarolim E. Anti-acid medication as a risk factor for food allergy. Allergy Eur J Allergy Clin Immunol. 2011;66(4):469–477.
- Liang CS, Bai YM, Hsu JW, et al. The risk of epilepsy after long-term proton pump inhibitor therapy. Seizure. 2021;87:88–93.
- Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapies. 2021;76(1):13–21.
- Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. IJERPH. 2019;16(9):1571.
- Malchodi L, Wagner K, Susi A, et al. Early acid suppression therapy exposure and fracture in young children. Pediatrics. 2019;144(1):10–12.
- Fleishman N, Richardson T, Attard T. The clinical characteristics of fractures in pediatric patients exposed to proton pump inhibitors. J Pediatr Gastroenterol Nutr. 2020;70(6):815–819.
- Matuszewska A, Nowak B, Jędrzejuk D, et al. Effect of long-term administration of ranitidine, a histamine H2 receptor antagonist, on bone metabolism in young growing rats. Pharmacol Rep. 2018;70(5):951–954.
- Liu X, Kumagai G, Wada K, et al. Suppression of osteogenic differentiation in mesenchymal stem cells from patients with ossification of the posterior longitudinal ligament by a histamine-2-receptor antagonist. Eur J Pharmacol. 2017;810:156–162.
- Park JH, Lee J, Yu SY, et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean Patients with GERD and peptic ulcer disease. BMC Geriatr. 2020;20(1):407.
- Grisso JA, Kelsey JL, O'Brien LA, et al. Risk factors for hip fracture in men. Hip fracture study group. Am J Epidemiol. 1997;145(9):786–793.
- Kinjo M, Setoguchi S, Solomon DH. Antihistamine therapy and bone mineral density: analysis in a population-based US sample. Am J Med. 2008;121(12):1085–1091.
- Kwok CS, Yeong JKY, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–776.
- Lyu B, Hansen KE, Jorgenson MR, et al. Associations between proton pump inhibitor and histamine-2 receptor antagonist and bone mineral density among kidney transplant recipients. Am J Nephrol. 2020;51(6):433–441.